×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| AUROBINDO PHARMA LTD. | 29319.4 | 5591.3 | 28481.7 | 9.63 | 61,061 | 18.0 |
| GLENMARK PHARMACEUTICALS LTD. | 24642.63 | 3302.26 | 23949.28 | 11.7 | 57874 | 43.5 |
| BIOCON LTD. | 5984.0 | -83.0 | 5371.0 | -0.07 | 48645 | 134.0 |
Aurobindo Pharma Ltd., with Security Code 524804, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,547.4 | 2,390.8 | 2,668.8 | 2,692.0 | 2,894.0 | 2,460.1 | 2,824.6 | 2,916.6 | 2,732.0 | 2,848.2 |
| Expenses | 2,855.6 | 1,968.4 | 2,123.6 | 2,210.3 | 2,119.2 | 1,961.2 | 2,103.7 | 2,203.5 | 2,135.4 | 2,051.8 |
| Operating Profit | 691.8 | 422.4 | 545.2 | 481.7 | 774.8 | 498.9 | 720.9 | 713.2 | 596.6 | 796.3 |
| OPM % | 19.5% | 17.67% | 20.43% | 17.89% | 26.77% | 20.28% | 25.52% | 24.45% | 21.84% | 27.96% |
| Other Income | 288.2 | 94.9 | 67.1 | 331.1 | 123.0 | 65.3 | 122.7 | 54.3 | 114.0 | 83.8 |
| Interest | 49.0 | 31.6 | 36.7 | 61.3 | 53.1 | 51.1 | 51.6 | 66.2 | 61.1 | 60.0 |
| Depreciation | 115.0 | 59.6 | 65.8 | 64.4 | 64.8 | 66.9 | 68.2 | 68.3 | 93.9 | 70.0 |
| Profit before tax | 816.0 | 426.0 | 509.8 | 687.2 | 779.9 | 446.2 | 723.8 | 632.9 | 555.6 | 750.1 |
| Tax % | -21% | -25.4% | -25.5% | -9.2% | -25.8% | -26.3% | -25.7% | -25.4% | -26.5% | 25.5% |
| Net Profit | 644.8 | 336.0 | 415.7 | 623.8 | 578.7 | 329.0 | 537.5 | 472.1 | 408.2 | 559.1 |
| EPS in Rs | 11 | 5.74 | 7.1 | 10.65 | 9.88 | 5.62 | 9.21 | 8.13 | 0 | 9.63 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,407.1 | 6,473.0 | 6,850.5 | 7,219.4 | 7,351.8 | 7,580.2 | 7,567.0 | 7,796.1 | 7,978.5 | 8,382.1 |
| Expenses | 5,453.3 | 5,476.6 | 5,702.0 | 5,846.0 | 5,753.1 | 5,920.0 | 5,948.8 | 6,229.9 | 6,400.5 | 6,622.3 |
| Operating Profit | 953.8 | 996.3 | 1,148.6 | 1,373.4 | 1,598.7 | 1,660.2 | 1,618.2 | 1,566.1 | 1,578.0 | 1,759.8 |
| OPM % | 14.89% | 15.39% | 16.77% | 19.02% | 21.75% | 21.9% | 21.38% | 20.09% | 19.78% | 20.99% |
| Other Income | 92.7 | 134.9 | 46.6 | 187.0 | 162.5 | 13.5 | 220.9 | 136.0 | 157.3 | 134.8 |
| Interest | 45.0 | 55.6 | 56.6 | 68.2 | 75.6 | 89.4 | 111.0 | 112.7 | 118.5 | 115.0 |
| Depreciation | 321.4 | 345.6 | 326.6 | 417.5 | 423.3 | 354.3 | 404.2 | 382.3 | 418.5 | 444.4 |
| Profit before tax | 680.1 | 730.1 | 881.8 | 1,074.7 | 1,262.4 | 1,352.0 | 1,323.9 | 1,207.2 | 1,198.3 | 1,335.1 |
| Tax % | -27.8% | -30.5% | -29.7% | -30.1% | -25.5% | -26% | -30.6% | -32.3% | -29.6% | -31.6% |
| Net Profit | 491.0 | 505.9 | 569.7 | 751.9 | 940.0 | 907.4 | 918.2 | 817.0 | 845.6 | 902.8 |
| EPS in Rs | 8.38 | 8.64 | 9.74 | 12.83 | 16.04 | 15.51 | 15.69 | 14 | 14.56 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -3% |
| 3 Years: | -12% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 5% |
| 3 Years: | -14% |
| TTM: | 0% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 10% |
| 3 Years: | 30% |
| 1 Year: | -3% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 8% |
| 3 Years: | 5% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 6% |
| 3 Years: | -1% |
| TTM: | 27% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 10% |
| 3 Years: | 30% |
| 1 Year: | -3% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|